Treatment as Prevention for Hepatitis C in Iceland
ConditionHepatitis C
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLandspitali University Hospital
About this trial
The main aim of this study is to test in the Icelandic population the hypothesis that a nationwide treatment program which offers effective treatment to all known cases of Hepatitis C with the aim of halting HCV (Hepatitis C virus) transmission will lead to a reduction in incidence and disease burden associated with chronic HCV infection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
HCV positive subjects 18 years and older, living in Iceland and covered by the Icelandic Health Insurance.
Disqualifiers
Age under 18 years
Inability to sign informed consent.
Trial population
All patients diagnosed with chronic HCV infection in Iceland
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupGroup A: Hepatitis C infected
Trial outcomes
Primary outcomes
1
Incidence of transmission of HCV in Iceland
Time frame
Measured annually for up to 15 yearsSecondary outcomes
1
Incidence of cirrhosis and hepatocellular carcinoma in Iceland
Time frame
Measured annually for up to 15 years2
Sustained virological response rate (SVR) to treatment with antiviral agents as measured by negative HCV RNA 12 weeks post treatment
Time frame
Measured for up to 36 months3
Reinfection rate as measured by new infections diagnosed in patients who were previously treated and achieved SVR
Time frame
Measured for up to 36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Landspitali University Hospital
Lead sponsor
National Center of Addiction Medicine (SAA)
Collaborator
Source ClinicalTrials.gov